Finafloxacin (MerLion Pharmaceuticals) is a fifth-generation fluoroquinolone under development for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis ( Table 1 ). There are three formulations available/in development, including a topical suspension which is licensed by the FDA and Health Canada for acute otitis externa. Additionally, intravenous (IV) and oral formulations have been evaluated in phase 1 and 2 clinical trials for cUTI. Finafloxacin binds to the bacterial DNA gyrase and topoisomerase IV preventing DNA replication. It is mainly differentiated from previous generations of the fluoroquinolones by its ability to retain antibacterial activity in acidic conditions, which is typical of infected body sites or in patients with acute sepsis (Higgins et al., 2010; Lemaire et al., 2011; Stubbings et al., 2011). Finafloxacin was shown to be superior to the second-generation fluoroquinolone ciprofloxacin in two cUTI/pyelonephritis clinical trials and retained potency against clinical strains shown to be resistant to ciprofloxacin (Vente et al., 2018; Wagenlehner et al., 2018).

Broad spectrum in vitro activity has been demonstrated for finafloxacin against Y. pestis, F. tularensis, B. pseudomallei, B. mallei, B. anthracis and C. burnetii at both neutral and acidic pH (Barnes et al., 2019; Peyrusson et al., 2021) ( Table 2 ). The MIC₉₀ values obtained for finafloxacin were low and comparable with standard-of-care antibiotics typically used as positive controls in these assays (fluoroquinolones and ceftazidime) with improved potency at acidic pH (Barnes et al., 2019). At pH 5 these were: ≤0.03 μg/mL (Y. pestis), 4 μg/mL (B. pseudomallei), 0.5 μg/mL (B. mallei) and ≤0.03 μg/mL (B. anthracis) and at pH 7: 0.06 μg/mL (Y. pestis), ≤0.03 μg/mL (F. tularensis), 4 μg/mL (B. pseudomallei), 0.5 μg/mL (B. mallei) and 0.12 μg/mL (B. anthracis). In addition, bactericidal activity was demonstrated in time kill assays against all of the bacterial agents, except for C. burnetii, where a cell culture model was used to demonstrate a 300-fold reduction in the intracellular bacterial load following finafloxacin treatment (Peyrusson et al., 2021) ( Table 2 ). It has been suggested that this improved activity is due to the rapid influx of finafloxacin into cells, the accumulation of high levels within the cell and a slow efflux rate out (Chalhoub et al., 2020).

In vivo efficacy of finafloxacin has also been demonstrated using an orally delivered human equivalent dose in murine models of inhalational tularaemia, plague, Q fever, melioidosis and glanders ( Table 2 ). Finafloxacin offered protection that was not statistically different to that afforded by ciprofloxacin and bacterial clearance when administered as treatment for plague. It was also comparable to co-trimoxazole as a treatment for glanders ( Table 2 ) (Barnes et al., 2021; Barnes et al., 2022). Finafloxacin offered a significant improvement in survival compared to ciprofloxacin and doxycycline for the treatment of melioidosis and ciprofloxacin for the treatment of tularaemia (Barnes et al., 2021; Barnes et al., 2022). In a non-lethal mouse model of Q fever, finafloxacin reduced the clinical signs of infection and weight loss when compared to ciprofloxacin and doxycycline (Hartley et al., 2021).

Delafloxacin (Melinta Therapeutics) is a fourth-generation fluoroquinolone, approved by the FDA and the EMA for the treatment of community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs) ( Table 1 ) (Melinta Therapeutics, 2017). Both IV and oral formulations are available, allowing for administration in both the inpatient and outpatient settings (McCurdy et al., 2023). Like finafloxacin, delafloxacin inhibits bacterial DNA gyrase and topoisomerase IV, and also has enhanced MICs at low pH, demonstrating a bactericidal effect against gram-negative and gram-positive organisms (Kocsis et al., 2021).

The MIC₉₀ values obtained for Y. pestis (0.016 μg/mL [pH 7.2]) and B. anthracis (≤0.001 μg/mL [pH 5.5] and 0.04 μg/mL [pH 7.2]), are low and comparable to those obtained for the fluoroquinolone class (0.016-0.06 μg/mL) ( Table 2 ) (Frean et al., 2003; McCurdy et al., 2023). The MIC₉₀ for B. pseudomallei (1 μg/mL) is comparable to standard-of-care antibiotics. Delafloxacin also demonstrates activity against B. pseudomallei overexpressing RND efflux pumps such as BpeEF-OprC (McCurdy et al., 2021; McCurdy et al., 2022).

Delafloxacin has been shown to be efficacious in murine models of inhalational melioidosis and anthrax ( Table 2 ). Delafloxacin afforded protection not significantly different to ciprofloxacin in mice infected with B. anthracis (McCurdy et al., 2023). Bacterial clearance was observed in the spleens of survivors from the anthrax study; however, lungs were colonized, likely due to spore persistence. When evaluated against inhalational melioidosis, delafloxacin offered a significant improvement in survival compared to ceftazidime and cleared colonizing bacteria from spleens (McCurdy et al., 2021).

Levofloxacin is a third-generation fluoroquinolone licensed by the MHRA and FDA for indications including pneumonia, rhinosinusitis, chronic bronchitis, pyelonephritis, urinary tract infections and skin or skin structure infections ( Table 1 ) (Podder et al., 2025). In addition, it is the only antibiotic discussed in this review which is licensed by the FDA for the treatment of Y. pestis and B. anthracis infections. Levofloxacin has the same mechanism of action as finafloxacin and delafloxacin and has broad spectrum activity against gram-negative and gram-positive organisms including methicillin resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis (Croom and Goa, 2003).

The MIC₉₀ values obtained for Y. pestis, F. tularensis, and B. anthracis are low (< 0.03, 0.06, and 0.25 μg/mL respectively) and comparable to those for other fluoroquinolones ( Table 2 ) (Frean et al., 1996; Cavallo et al., 2002; Urich and Petersen, 2008). Similarly, the MIC₉₀s for B. pseudomallei and B. mallei (2 μg/mL and 1 μg/mL respectively) are comparable with comparator antibiotics (Thibault et al., 2004). There is limited in vitro data generated for C. burnetii, however an MIC of 1 μg/mL has been reported for strain Nine Mile (Phase I) with an intracellular MIC of 0.16 μg/mL (Clay et al., 2021; Hartley et al., 2021).

In vivo efficacy studies delivering the antibiotic by the IV and oral routes have been performed in murine and non-human primate (NHP) models ( Table 2 ). Levofloxacin completely protected animals and cleared bacteria from tissues in an African Green Monkey (AGM) model of plague and a marmoset model of tularaemia (Nelson et al., 2010; Layton et al., 2011). Delaying treatment resulted in a reduction in survival in the AGM (Campbell et al., 2020). High levels of protection and clearance was also demonstrated in a rhesus macaque model of anthrax treated with levofloxacin (Kao et al., 2006).

Levofloxacin provided complete protection when delivered early in a murine model of plague (Heine et al., 2007). High levels of protection were demonstrated when levofloxacin was delivered following an intranasal challenge of F. tularensis and B. mallei (Judy et al., 2004; Klimpel et al., 2008). Limited information is available for the in vivo evaluation of B. pseudomallei infections with levofloxacin as fluoroquinolones are not clinically recommended for melioidosis; however, 55% survival was reported when a suboptimal course of levofloxacin was initiated at 6 hours post-challenge in a mouse model (D'Elia et al., 2019). Levofloxacin delivered by the intraperitoneal route reduced weight loss and the development of clinical signs of disease in a mouse model of Q fever (Clay et al., 2021).

Omadacycline (Paratek Pharmaceuticals) is a first-in-class aminomethylcycline of the tetracycline family, approved by the FDA in 2018 for the treatment of CABP and ABSSSIs (Watkins and Deresinski, 2019) ( Table 1 ). In addition, it is the first once-daily multi-indication oral antibiotic to be approved by the FDA in 10 years (Watkins and Deresinski, 2019). Both oral and IV formulations are available. Mechanistically, it binds the 30S ribosomal subunit, preventing the binding of aminoacyl-tRNA and inhibiting protein synthesis. Omadacycline is active against a wide range of pathogens including MRSA, vancomycin resistant Enterococcus and penicillin resistant S. pneumoniae (Tanaka et al., 2016).

The MIC₉₀ obtained for Y. pestis (1 μg/mL), which, whilst higher than the previously discussed fluoroquinolones, is within the range of susceptible gram-negative pathogens for the class ( Table 2 ) (Steenbergen et al., 2017). The MIC₉₀ for B. anthracis has been reported as 0.06 μg/mL and 0.03 μg/mL which is comparable to previous generations of the fluoroquinolones (Steenbergen et al., 2017; Heine et al., 2024). Omadacycline also demonstrated high potency against the ciprofloxacin-resistant strain of Ames (BAC’4-2) (Heine et al., 2024).

In vivo efficacy delivering the antibiotic by the IP route has also been demonstrated in murine models of inhalational plague and anthrax ( Table 2 ). Omadacycline was shown to offer an equivalent level of protection to ciprofloxacin when administered as treatment for infection with Y. pestis (Steenbergen et al., 2017). Bacterial clearance was observed in spleens. When evaluated against infection with B. anthracis, omadacycline also offered an equivalent level of protection to ciprofloxacin ( Table 2 ) (Steenbergen et al., 2017). Spleens were clear from colonizing bacteria in survivors. In a separate study, omadacycline provided complete protection in an inhalational anthrax mouse model with strain BAC’4-2 (Heine et al., 2024).

Gepotidacin (GSK) is a bactericidal first-in-class triazaacenaphthylene that was recently approved by the FDA for the treatment of uncomplicated UTIs (uUTIs) (Wagenlehner et al., 2024) ( Table 1 ). It is also in development for the treatment of gonorrhoea and both oral and IV formulations have been produced. Gepotidacin inhibits bacterial DNA gyrase and the type IIA topoisomerase at a site and mechanism distinct from the fluoroquinolones. As the first approved novel bacterial topoisomerase inhibitor (NBTI), gepotidacin is of interest as its potency is not impaired by the on-target mutations associated with fluoroquinolone resistance. Two phase 3 clinical trials evaluating gepotidacin as a therapeutic for uUTIs were stopped early due to the superiority of results obtained, leading to the FDA approving the use for the treatment of uUTIs in female adults and paediatric patients over 12 (GSK, 2022; GSK, 2025). Gepotidacin has demonstrated in vitro activity against gram-positive and gram-negative organisms, including MRSA, Shigella species, S. pneumoniae and Mycobacteria (Biedenbach et al., 2016; Ahmad et al., 2022).

Potency has been demonstrated in vitro for gepotidacin against Y. pestis, F. tularensis, and B. anthracis, all with MIC₉₀ values between 0.5 and 1 μg/mL ( Table 2 ) (Jakielaszek et al., 2022; Jakielaszek et al., 2023; Hilliard et al., 2024). It is worth noting that the in vitro MIC screening with gepotidacin utilised large panels of bacterial strains (120+), which is impressive. It also retained activity against aminoglycoside and doxycycline resistant mutants of Y. pestis and fluoroquinolone resistant mutants of B. anthracis (Jakielaszek et al., 2022; Hilliard et al., 2024).

Several studies utilizing large animal models have been published that demonstrate the efficacy of gepotidacin against Y. pestis, F. tularensis, and B. anthracis. This includes in vivo efficacy data in NHP models of plague and tularaemia where fever was used as a trigger-to-treat ( Table 2 ). Gepotidacin provided a high level of protection (75-100%) and bacterial clearance in an AGM model of inhalational plague, irrespective of the antibiotic dose and dosing regimen (Jakielaszek et al., 2022). There were no differences between the level of protection offered in relation to the number of doses of antibiotic administered. This is similar to the data previously generated for ciprofloxacin and levofloxacin in this NHP model (Layton et al., 2011; Campbell et al., 2020). When administered to cynomolgus macaques following an inhalational F. tularensis exposure, gepotidacin provided complete protection and bacterial clearance (Jakielaszek et al., 2023). This is similar to data generated with levofloxacin in a marmoset model of tularaemia (Nelson et al., 2010). Gepotidacin was also shown to be 90% protective in a lethal, trigger-to-treat New Zealand white rabbit model of inhalational anthrax (Hilliard et al., 2024).

Tebipenem pivoxil hydrobromide (Spero Therapeutics) is an oral carbapenem prodrug being developed for the treatment of cUTIs ( Table 1 ). Carbapenems are bactericidal agents that enter the periplasm space and acylate penicillin-binding proteins (PBPs). This weakens the peptidoglycan of the cell wall which lyses the bacterial cell (Mahalingam and Shenoy, 2020). Traditionally, carbapenems have only been available for IV administration; therefore, the potential to leverage carbapenem activity in an orally-available drug would be significant. Tebipenem has been evaluated in a phase 3 clinical trial for the treatment of cUTIs and pyelonephiritis; however, the FDA has requested further data to be generated and submitted before considering licensure. Tebipenem is active against gram-negative and gram-positive organisms including extended spectrum β-lactamase (ESBL) and AmpC β-lactamase producing Klebsiella pneumoniae, Escherichia coli, Proteus spp, and MRSA (Cotroneo et al., 2020).

The MIC₉₀ values obtained for Y. pestis, B. pseudomallei, B. mallei and B. anthracis are low (0.03, 2, 1 and 0.008 μg/mL, respectively ( Table 2 )) (Seenama et al., 2013; Clayton et al., 2021). The MIC for a ciprofloxacin resistant Ames strain of B. anthracis was similar (0.008 μg/mL). There was no measurable in vitro activity for F. tularensis (MIC₉₀ of > 64 μg/mL), which is consistent with the activity of other carbapenems (Caspar and Maurin, 2017).

Oral tebipenem has been evaluated in murine models of pneumonic plague and inhalational anthrax ( Table 2 ). It offered an equivalent level of protection to ciprofloxacin when administered as treatment for infection with Y. pestis (Clayton et al., 2021). Bacterial clearance was observed in lungs, livers and spleens. When evaluated against an infection with B. anthracis, tebipenem also offered an equivalent level of protection to ciprofloxacin (Clayton et al., 2021). Spleens were clear at the end of the study with lungs colonized.

Sulopenem (Iterum Therapeutics) is a broad spectrum thiopenem β-lactam, being developed for the treatment of infections caused by multi-drug resistant bacteria ( Table 1 ). Two formulations are currently being evaluated, an orally-available prodrug (sulopenem etzadroxil) or sulopenem for IV administration. Sulopenem retains many characteristics of the carbapenem family and shares the same mechanism of action (Zhanel et al., 2022). It has been evaluated in multiple phase clinical 3 trials for the treatment of uUTIs, cUTIs and pyelonephritis and is active against gram-negative and gram-positive organisms including penicillin resistant S. pneumoniae and H. influenzae and M. catarrhalis strains able to produce β-lactamases (Butler et al., 2023; Dunne et al., 2023). It was recently approved by the FDA to treat uUTIs in adult women with limited or no alternative oral antibacterial treatment options (delivered with the renal tubular transport inhibitor probenecid) (FDA, 2024).

The MIC₉₀ values obtained for Y. pestis, B. pseudomallei, B. mallei and B. anthracis are low (0.12, 1, 0.5 and 0.03 μg/mL, respectively and similar to carbapenems (Dunne et al., 2021) ( Table 2 ). Like tebipenem, there is limited in vitro activity for sulopenem against strains of F. tularensis (MIC₉₀ of 32 μg/mL). Sulopenem has been evaluated for efficacy in a murine model of inhalational anthrax where it offered an equivalent level of protection to ciprofloxacin ( Table 2 ) (Puttagunta et al., 2022). Spleens were clear of bacteria at the end of the study with lungs colonized.